MetaCap

Novavax (NVAX) vs Recursion Pharmaceuticals (RXRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novavax (NVAX) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 15.5% versus a loss of 41.2%. Over five years, RXRX leads with a -87.0% price change compared with -96.6% for NVAX. Recursion Pharmaceuticals is the larger company by market cap ($1.53 billion vs $1.23 billion), about 1.2 times the size, while Novavax is growing revenue faster (+64.7% vs +26.9%).

Novavax converts more of its revenue into profit, with a net margin of 39.2% versus -863.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVAX+15.46%RXRX-41.25%
+105%+28%-48%
Nov 21, 20251 yearNov 20, 2026
NVAX-96.12%RXRX-87.63%
+19%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVAX versus RXRX key metrics
MetricNVAXRXRX
Share price$7.47$2.45
Market cap$1.23B$1.53B
1-day change-3.24%-9.93%
YTD return+11.16%-40.10%
1-year return+15.46%-41.25%
5-year return-96.57%-87.04%
EPS (TTM)$-0.52$-0.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.12B$74.68M
Revenue growth (YoY)+64.69%+26.92%
Net income (latest FY)$440.30M$-644.76M
Gross margin93.50%4.99%
Operating margin40.30%-867.87%
Net margin39.19%-863.35%
52-week high$13.39$5.24
52-week low$6.36$2.44
Distance from 52-week high-44.21%-53.24%
Analyst consensusbuybuy
Avg. price target upside+88.89%+176.33%
Average volume6.67M24.47M
Shares outstanding165.01M622.76M
Employees749600
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVAX has outperformed RXRX by 56.7 percentage points over the past year.
  • Novavax is more profitable, keeping 39.2 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
  • Novavax grew revenue faster in its latest fiscal year (+64.69% vs +26.92%).

About Novavax

NVAX stock →

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

NVAX vs RXRX FAQ

Which is bigger, Novavax or Recursion Pharmaceuticals?

Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $1.53B compared with $1.23B for Novavax (NVAX).

Which stock has performed better over the past year, NVAX or RXRX?

NVAX returned +15.46% over the past 12 months, compared with -41.25% for RXRX (price return, excluding dividends). Past performance does not predict future results.

Are Novavax and Recursion Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons